HER2 can also be targeted with trastuzumab emtansine, which is a conjugate between trastuzumab and the cytotoxic reagent emtansine used to treat HER2+ breast and lung cancers [60,61]. This evidence concerns the gene ERBB2 and lung carcinoma.